Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic
R Solante, C Alvarez-Moreno, E Burhan… - Expert review of …, 2023 - Taylor & Francis
Introduction COVID-19 vaccines have been highly effective in reducing morbidity and
mortality during the pandemic. However, the emergence of the Omicron variant and …
mortality during the pandemic. However, the emergence of the Omicron variant and …
Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 …
MH Kyaw, J Spinardi, L Zhang, HML Oh… - Human Vaccines & …, 2023 - Taylor & Francis
Introduction of primary COVID-19 vaccination has helped reduce severe disease and death
caused by SARS-CoV-2 infection. Understanding the protection conferred by heterologous …
caused by SARS-CoV-2 infection. Understanding the protection conferred by heterologous …
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged≥ 18 …
JD Wu, JX Li, J Liu, HM Wang, GH Zhou, J Li… - The Lancet Infectious …, 2023 - thelancet.com
Background Heterologous boosting is suggested to be of use in populations who have
received inactivated COVID-19 vaccines. We aimed to assess the safety and …
received inactivated COVID-19 vaccines. We aimed to assess the safety and …
[HTML][HTML] Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens
S Kanokudom, J Chansaenroj, N Suntronwong… - International Journal of …, 2023 - Elsevier
Objectives To report the safety and immunogenicity profile of a protein subunit vaccine
(Covovax TM) given as a third (booster) dose to individuals primed with different primary …
(Covovax TM) given as a third (booster) dose to individuals primed with different primary …
[HTML][HTML] Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac …
E Fadlyana, D Setiabudi, CB Kartasasmita… - The Lancet Infectious …, 2023 - thelancet.com
Background Inactivated COVID-19 vaccines effectively prevent death, but their effectiveness
for preventing infection or severe illness is known to decrease within 3–6 months following …
for preventing infection or severe illness is known to decrease within 3–6 months following …
[HTML][HTML] Validation of a SARS-CoV-2 surrogate neutralization test detecting neutralizing antibodies against the major variants of concern
E Santos da Silva, JY Servais, M Kohnen… - International Journal of …, 2023 - mdpi.com
SARS-CoV-2 infection and/or vaccination elicit a broad range of neutralizing antibody
responses against the different variants of concern (VOC). We established a new variant …
responses against the different variants of concern (VOC). We established a new variant …
[HTML][HTML] Single Ad26. COV2. S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open …
S Muangnoicharoen, R Wiangcharoen, S Nanthapisal… - Vaccine, 2023 - Elsevier
Background The inactivated COVID-19 whole-virus vaccine BBIBP-CorV has been
extensively used worldwide. Heterologous boosting after primary vaccination can induce …
extensively used worldwide. Heterologous boosting after primary vaccination can induce …
[HTML][HTML] Characterization of immune responses to two and three doses of the adenoviral vectored vaccine ChAdOx1 nCov-19 and the whole virion inactivated vaccine …
A Chaudhary, R Madhavan, S Babji, R Raju, C Syed… - Vaccine, 2023 - Elsevier
Infections with SARS-CoV-2 variants and declining immunity after primary vaccination,
encouraged the use of booster doses. Some countries changed their immunization …
encouraged the use of booster doses. Some countries changed their immunization …
[HTML][HTML] SARS-CoV-2 vaccine uptake among patients with chronic liver disease: a cross-sectional analysis in Hebei Province, China
Y Liu, W Yuan, H Zhan, H Kang, X Li, Y Chen, H Li… - Vaccines, 2023 - mdpi.com
Chronic liver disease (CLD) patients have higher mortality and hospitalization rates after
infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study …
infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study …
[HTML][HTML] A two-arm analysis of the immune response to heterologous boosting of inactivated SARS-CoV-2 vaccines
A Nithichanon, L Kamuthachad, K Salao… - Scientific Reports, 2023 - nature.com
Several vaccine programs were introduced during the COVID-19 pandemic, which included
inactivated virus, DNA viral vectors and mRNA vaccines. Booster programs are …
inactivated virus, DNA viral vectors and mRNA vaccines. Booster programs are …